Elite Pharmaceuticals Inc (ELTP)

[WeeZuhl]

Seeking Alpha: All subjects enrolled and dosed in Elite Pharma's late-stage trial of abuse-deterrent opioid


http://seekingalpha.com/news/2684335-all-subjects-enrolled-and-dosed-in-elite-pharmas-late-stage-trial-of-abuse-deterrent-opioid?uprof=45#email_link


Aug 3 2015, 10:12 ET | About: Elite Pharmaceuticals,... (ELTP) | By: Douglas W. House, SA News Editor Contact this editor with comments or a news tip

163 patients have been enrolled and dosed in a Phase 3 study assessing Elite Pharmaceuticals' (OTCQB:ELTP -0.8%) abuse-deterrent opioid, ELI-200, for the treatment of severe post-surgical pain. Top-line data are expected by year end.ELI-200's abuse-deterrent technology, called ART, is a multi-particulate capsule that contains the opioid antagonist naltrexone. When taken as intended, the naltrexone passes through the body unreleased while the opioid agonist is released over time to relieve pain. If the multi-particulate beads are crushed or dissolved, the naltrexone is released which blocks the opioid-associated euphoria.